Learn more about the current challenges in diagnosing bloodstream infections that lead to sepsis, and how culture-independent diagnostics may impact patient outcomes.#Sepsis #AntimicrobialResistance #Laboratory #Hospital
- May 13, 2022
Effective October 1, 2019, Medicare will provide an add-on payment for the T2Bacteria Panel of up to $97.50 per qualifying case to Inpatient Prospective Payment System (IPPS)-participating acute care hospitals. This add-on payment will be incremental to the Medicare Severity-Diagnosis Related Group (MS-DRG) reimbursement for qualifying Medicare inpatient cases based on the cost of the case. Hospitals report the use of the T2Bacteria Panel by recording an ICD-10 procedure code (ICD-10-PCS code) on the claim billed to Medicare. The codes accompany the other ICD-10-PCS codes billed for the inpatient services.
Summary of the NTAP details for T2Bacteria Panel:
Effective date for NTAP: October 1, 2019
Eligible facilities: IPPS-participating acute care hospitals
Setting of care: IPPS inpatient hospital
Eligible patients: Medicare-eligible patients
ICD-10-PCS code: XXE5XM5 (Measurement of Infection, Whole Blood Nucleic Acid-base MicrobialDetection, New Technology Group 5)
Amount of NTAP: Up to $97.50 per qualifying case
“The T2Bacteria Test Panel represents a substantial clinical improvement over existing technologies because it reduces the proportion of patients on inappropriate therapy, thus reducing the rate of subsequent diagnostic or therapeutic intervention as well as length of stay and mortality rates caused by sepsis causing bacterial infections.”2
Species identification in just hours: Data generated by T2Bacteria users demonstrate its ability to benefit patients in the emergency department by providing information that leads to more rapid time to delivery of effective therapy, de-escalation of unnecessary therapy, and helping avoid premature discharge and readmission to the emergency department.3
T2Bacteria identifies:
To learn more about the New Technology Add-on Payment, please contact us.
*A combination of samples was run in both the prospective and contrived arms of the study. T2Bacteria showed an overall average sensitivity of 90% in the prospective arm of the study, with an overall average PPA of 97% in the contrived arm of the study.
1. Nguyen, M. H., et al. (2019) Performance of the T2Bacteria Panel for Diagnosing Bloodstream Infections. A Diagnostic Accuracy Study. Annals of Internal Medicine.
2. United States CMS FY 2020 inpatient prospective payments system final rule
3. Voigt, Christopher, et al. “The T2Bacteria assay Is a sensitive and rapid detector of bacteremia that can be initiated in the emergency department and has potential to favorably influence subsequent therapy.” The Journal of emergency medicine 58.5 (2020): 785-796.
4. Karlowsky, JA, et al. Annals of Clinical Microbiology and Antimicrobials, 2004
Sensitivity: 90%1,*
Specificity: 98%1,*
E. faecium
S. aureus
K. pneumoniae
P. aeruginosa
E. coli
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
© 2022 T2 Biosystems, Inc.
Please tell us where you are visiting from: United States | Outside the United States